Overview
Cerebral metastases represent a significant problem for oncological management. It is estimated that 20-40% of patients with cancer will develop metastatic cancer to the brain during the course of their illness. 18F-fluoropivalate ([18F]FPIA) is a new tracer that images short chain fatty acid (SCFA) uptake in tumours, a key component of fatty acid oxidation.
The aim of this study is to quantify the degree of early step fatty acid oxidation in cerebral metastases as imaged by [18F]FPIA Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI).
The investigators hypothesise that FPIA uptake will be higher in metastases that are treatment naïve compared to those that have undergone treatment, in keeping with viable tumour cells having a high propensity to generate ATP and NADPH via fatty acid oxidation under bioenergetic stress.
Description
24 evaluable patients with radiological evidence of cerebral metastases on MRI will be enrolled into the study (12 who are treatment naïve + 12 who have completed Stereotactic Radiosurgery (SRS)+/- combination therapy). The patients invited to participate in the study will provide written informed consent. [18F]FPIA PET/MRI imaging will only be performed once patients have satisfied the inclusion and exclusion criteria. Once these have been satisfied, eligible patients will proceed to [18F]FPIA PET/MRI.
On the day of imaging the patients will undergo a blood test to measure plasma concentrations of carnitine (approximately 6mls). During the scan, a single dose of [18F]FPIA (maximum, 370 MBq) IV will be administered to the participant followed by a whole brain dynamic PET/MRI scan over 66 minutes. During the MRI sequences, the patient will receive a 2 stage IV bolus of Gadolinium contrast medium administered through a peripheral venous cannula.
Eligibility
Inclusion Criteria:
- Treatment naïve
or
B) SRS+/- combination treated - Patients that have completed the SRS part of a combination
regime enabling a 4-8 week post-SRS treatment PET/MRI scan.
and
C) That fulfil the following criteria:
1. Age ≥18.
2. Target metastases size ≥ 1cm.
3. WHO performance status 0 - 2.
4. If female, the subject is either post-menopausal (at least 1 year), or surgically
sterilized (has had a documented bilateral oophorectomy and/or documented hysterectomy
for at least 2 years), or if of childbearing potential, must have a negative urine
beta human chorionic gonadotropin (beta-hCG) pregnancy test done prior to tracer
administration.
5. The subject is able and willing to comply with study procedures, and signed and dated
informed consent is obtained.
6. The subject has a satisfactory medical history as judged by the investigator with no
significant co-morbidities.
7. The subject's clinical and laboratory tests are within normal limits and/or considered
clinically insignificant.
Exclusion Criteria:
1. The subject is pregnant or lactating.
2. Any other chronic illness that will or musculoskeletal condition that would not allow
comfortable performance of a PET study.
3. Prior use within 14 days of enrolment or concurrent therapy with any other
investigational agent.
4. Unsatisfactory renal function (eGFR<30).
5. The subject has non-MRI compatible devices (e.g.a pacemaker, an implantable
cardioverter-defibrillator (ICD), a nerve stimulator, a cochlear implant or a drug
pump) or implanted material (e.g. non-MRI compatible sternal wires, biostimulators,
metals or alloys).